Prenetics Global Limited Q1 FY2026 Earnings Call
· Earnings call transcript and AI-powered summary
Prenetics Q1 2026 Earnings Summary
Company Context and Transformation
- Prenetics has shifted from a diagnostics/genome testing business (public in 2022) to a consumer health company anchored by IM8, a premium supplement brand with recurring subscription revenue, global distribution to 43 countries, and focus on unit economics.
- Over the past 9 months, divested ACT Genomics, Europa, and Insighta to redeploy capital into IM8 growth.
- IM8 launched 17 months ago with zero revenue; now shipping ~150,000 servings daily and tracking toward ~$186M annualized recurring revenue based on May monthly revenue.
Financial Highlights (Q1 2026 vs. Prior Periods)
- Total revenue: $36 million on a continuing operations basis, up ~333-334% year-over-year from $8.3 million in Q1 2025.
- IM8 revenue: $33.8 million, nearly 6x year-over-year and up 23% sequentially from Q4 2025.
- Gross profit: $23.3 million, up 315% year-over-year.
- Consolidated gross margin: 64.8%; IM8 gross margin expanded to 64.3%, up ~400 basis points sequentially from Q4 2025 (and from 59.6% a year ago), driven by manufacturing efficiencies, supplier negotiations, favorable mix toward subscriptions, packaging optimization, and fulfillment improvements.
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional